Public debate on the rising cost of new biotechnology drug treatments has intensified over the last few years as healthcare budget pressures have mounted under a strained economy. Meanwhile, the demand for new, effective medical and drug treatments continues to rise as unhealthy lifestyles cause further increases in diabetes and cardiovascular disease. Global drug pricing is one of the most hotly debated yet least understood aspects of the pharmaceutical industry. How should drug prices be set and what does it mean for patients? Why do governments increasingly get involved, and what is its impact on the global competitive environment? How can a life-saving industry have a poorer image than gun and tobacco industries, whose products are associated with death? Ed Schoonveld explains how pharmaceutical prices are determined in a complex global payer environment and what factors influence the process. His insights will help a wide range of audiences, from healthcare industry professionals to policy makers and the broader public, to gain a better understanding of this highly complex and emotionally charged field. The Price of Global Health is recognized as a valued and unique reference book that covers a complete array of topics related to global pharmaceutical pricing. It contains an in-depth but straightforward exploration of the pharmaceutical pricing strategy process, its underlying market access, general business and ethical considerations, and its implications for payers, physicians and patients. It is a much-needed and invaluable resource for anybody interested or involved in, or affected by, the development, funding and use of prescription drugs. In particular, it is of critical importance to pharmaceutical company executives and other leaders and professionals in commercialization and drug development, including marketing, business development, market access and pricing, clinical development, drug discovery, regulatory affairs, health outcomes, market research and public affairs. The second edition includes new chapters on payer value story development, oncology, orphan drugs and payer negotiations. Furthermore, many country chapters have been substantially updated to reflect changes in the healthcare systems, including the Affordable Care Act in the US, AMNOG in Germany, medico-economic requirements in France and many other country-specific changes. Lastly, almost every chapter has been updated with new examples and illustrations.

Book by Reekie, W. Duncan, Weber, Michael H.

Product Description: New physician-recommended ways to save thousands of dollars per year on prescription drugs.With the pharmaceutical industry spending $8 billion per year on direct marketing to physicians, everyone winds up paying the bill through escalating prescription costs...read more

Demonstrates that important new drugs are the results of work done at taxpayer-funded universities and at the National Institutes of Health, not by the pharmaceutical firms who profit from the sale of prescription drugs.

Product Description: Over the years, many countries have approached the World Health Organization for advice or information on the feasibility of measures to control the growth of expenditure on medicines. Such calls for help led the Organization to undertake a study as early as 1983...read more

Product Description: Readers of Studies in Pharmaceutical Economics learn the value of economic research in forming health policy while they develop an understanding of the various factors that influence the cost of pharmaceutical care for patients, pharmacists, physicians, and manufacturers...read more

Product Description: This volume examines various aspects of the continuing policy dispute and offers several views on the future of the pharmaceutical industry.